Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) saw a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 20,390 shares, a decline of 70.4% from the May 31st total of 68,896 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average trading volume of 76,356 shares, the short-interest ratio is currently 0.3 days.

Matinas Biopharma Stock Up 3.1%

Shares of NYSEAMERICAN:MTNB traded up $0.02 during midday trading on Friday, reaching $0.64. The company’s stock had a trading volume of 52,415 shares, compared to its average volume of 68,658. The firm has a market cap of $4.12 million, a price-to-earnings ratio of -0.32 and a beta of 1.67. Matinas Biopharma has a 1 year low of $0.48 and a 1 year high of $3.09. The business has a 50 day moving average price of $0.67 and a 200 day moving average price of $0.64.

Get Matinas Biopharma alerts:

Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.30) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC acquired a new position in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma as of its most recent SEC filing. 11.77% of the stock is owned by hedge funds and other institutional investors.

About Matinas Biopharma

(Get Free Report)

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.

Featured Articles

• Five stocks we like better than Matinas Biopharma
• As Stablecoins Keep Growing, These 2 Stocks Benefit
• Apple Just Handed These 4 Memory Stocks Their Best News of the Year
• Costco’s Secret Growth Engine May Be Running Out of Gas
• Why Alphabet’s Pullback May Be an Opportunity in Disguise

Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.